These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 21809115

  • 1. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [Abstract] [Full Text] [Related]

  • 2. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 3. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A.
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 10. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.
    J Clin Oncol; 2008 Nov 01; 26(31):5027-35. PubMed ID: 18768436
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Nov 01; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group.
    Lancet Oncol; 2011 Nov 01; 12(12):1134-42. PubMed ID: 21917518
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
    Martin-Richard M, Muñoz M, Albanell J, Colomo L, Bellet M, Rey MJ, Tabernero J, Alonso C, Cardesa A, Gascon P, Fernandez PL.
    Oncology; 2004 Nov 01; 66(5):388-94. PubMed ID: 15331926
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D.
    Eur J Cancer; 2008 Dec 01; 44(18):2791-8. PubMed ID: 18993056
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.